Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Mutation”

108 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 108 results

Early research (Phase 1)Active Not RecruitingNCT04521686
What this trial is testing

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Eli Lilly and Company 200
Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Not applicableApproved For MarketingNCT05592743
What this trial is testing

Vorasidenib Expanded Access Program

Who this might be right for
GliomaRecurrenceDisease Attributes+10 more
Servier
Testing effectiveness (Phase 2)Looking for participantsNCT03471260
What this trial is testing

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 96
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Not applicableLooking for participantsNCT07142226
What this trial is testing

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

Who this might be right for
Biliary Tract Cancer
CHA University 200
Testing effectiveness (Phase 2)Looking for participantsNCT06501625
What this trial is testing

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Who this might be right for
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier 52
Not applicableUnknownNCT02333513
What this trial is testing

Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Who this might be right for
Recurrent High-grade Glioma
Hebei Yanda Hospital 100
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Early research (Phase 1)Looking for participantsNCT05873686
What this trial is testing

Clinical Study of NXP900 in Subjects With Advanced Cancers

Who this might be right for
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal Cancer+3 more
Nuvectis Pharma, Inc. 140
Testing effectiveness (Phase 2)Looking for participantsNCT07604064
What this trial is testing

A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

Who this might be right for
Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
Kissei Pharmaceutical Co., Ltd. 3
Testing effectiveness (Phase 2)Looking for participantsNCT07471841
What this trial is testing

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Who this might be right for
IDH1 MutationRelapsed / Refractory AML
Timothy Pardee 25
Very early researchActive Not RecruitingNCT05406700
What this trial is testing

Niraparib In Recurrent IDH 1/2 Gliomas

Who this might be right for
Low-grade GliomaIDH2 Gene MutationRecurrent Glioma+2 more
Massachusetts General Hospital 16
Not applicableLooking for participantsNCT07151118
What this trial is testing

CtDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
CHA University 100
Testing effectiveness (Phase 2)Looking for participantsNCT07286292
What this trial is testing

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Who this might be right for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Institut de Recherches Internationales Servier (I.R.I.S.) 10
Testing effectiveness (Phase 2)WithdrawnNCT06597734
What this trial is testing

Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03503409
What this trial is testing

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463768
What this trial is testing

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Who this might be right for
Acute Myeloid Leukemia
French Innovative Leukemia Organisation 60
Testing effectiveness (Phase 2)Looking for participantsNCT06611839
What this trial is testing

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Who this might be right for
AMLIDH1 MutationTreatment
Institute of Hematology & Blood Diseases Hospital, China 23
Next Page